Stocks & Investing
Fri, August 16, 2024
[ 12:00 AM ] - WOPRAI
Fri, August 9, 2024
[ 12:00 AM ] - WOPRAI
Fri, August 2, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Wed, July 17, 2024
[ 12:00 AM ] - WOPRAI
Tue, June 4, 2024
[ 12:00 AM ] - WOPRAI
Fri, May 3, 2024
[ 12:00 AM ] - WOPRAI
Fri, February 16, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Thu, February 8, 2024
[ 12:00 AM ] - WOPRAI
Wed, February 7, 2024
[ 12:00 AM ] - WOPRAI
Wed, January 31, 2024
[ 12:00 AM ] - WOPRAI
Tue, January 9, 2024
[ 12:00 AM ] - WOPRAI
Thu, November 9, 2023
[ 12:00 AM ] - WOPRAI
Fri, November 3, 2023
[ 12:00 AM ] - WOPRAI
Wed, September 13, 2023
[ 12:00 AM ] - WOPRAI
Tue, August 15, 2023
[ 12:00 AM ] - WOPRAI
Fri, June 23, 2023
[ 12:00 AM ] - WOPRAI
Thu, March 2, 2023
[ 12:00 AM ] - WOPRAI
Wed, March 1, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Fri, February 24, 2023
[ 12:00 AM ] - WOPRAI
Fri, January 20, 2023
[ 12:00 AM ] - WOPRAI
Thu, November 17, 2022
[ 12:00 AM ] - WOPRAI
Wed, November 9, 2022
[ 12:00 AM ] - WOPRAI
Fri, November 4, 2022
[ 12:00 AM ] - WOPRAI
Thu, November 3, 2022
[ 12:00 AM ] - WOPRAI
Mon, October 31, 2022
[ 12:00 AM ] - WOPRAI
Fri, October 28, 2022
[ 12:00 AM ] - WOPRAI
Salveen Richter Upgraded (ALNY) to Strong Buy and Increased Target to $370 on, Aug 16th, 2024
Salveen Richter of Goldman Sachs, Upgraded "Alnylam Pharmaceuticals, Inc." (ALNY) to Strong Buy and Increased Target from $198 to $370 on, Aug 16th, 2024.
Salveen has made no other calls on ALNY in the last 4 months.
There are 17 other peers that have a rating on ALNY. Out of the 17 peers that are also analyzing ALNY, 4 agree with Salveen's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Tiago Fauth of "Wells Fargo" Maintained at Hold with Increased Target to $233 on, Friday, August 2nd, 2024
- Olivia Brayer of "Cantor Fitzgerald" Maintained at Hold with Increased Target to $220 on, Monday, July 22nd, 2024
- Michael Ulz of "Morgan Stanley" Maintained at Hold with Increased Target to $255 on, Friday, July 12th, 2024
- Jessica Fye of "JP Morgan" Maintained at Hold with Increased Target to $248 on, Wednesday, July 3rd, 2024
These are the ratings of the 13 analyists that currently disagree with Salveen
- David Lebovitz of "Citigroup" Maintained at Strong Buy with Increased Target to $342 on, Friday, August 2nd, 2024
- Gary Nachman of "Raymond James" Maintained at Buy with Increased Target to $275 on, Friday, August 2nd, 2024
- Gena Wang of "Barclays" Maintained at Buy with Increased Target to $295 on, Friday, August 2nd, 2024
- Joseph Stringer of "Needham" Maintained at Strong Buy with Increased Target to $320 on, Friday, August 2nd, 2024
- Luca Issi of "RBC Capital" Maintained at Buy with Increased Target to $300 on, Friday, August 2nd, 2024
- Whitney Ijem of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $366 on, Friday, August 2nd, 2024
- Eliana Merle of "UBS" Maintained at Strong Buy with Increased Target to $288 on, Friday, June 28th, 2024
- Paul Matteis of "Stifel" Maintained at Strong Buy with Increased Target to $295 on, Thursday, June 27th, 2024
- Ritu Baral of "TD Cowen" Maintained at Strong Buy with Increased Target to $282 on, Tuesday, June 25th, 2024
- Liisa Bayko of "Evercore ISI Group" Maintained at Buy with Increased Target to $260 on, Tuesday, June 25th, 2024
- Kostas Biliouris of "BMO Capital" Maintained at Buy and Held Target at $234 on, Monday, June 24th, 2024
- Patrick Trucchio of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $400 on, Monday, June 24th, 2024
- Keay Nakae of "Chardan Capital" Maintained at Strong Buy and Held Target at $225 on, Friday, May 3rd, 2024
